Musther Helen, Olivares-Morales Andrés, Hatley Oliver J D, Liu Bo, Rostami Hodjegan Amin
Simcyp Limited (a Certara Company), Blades Enterprise Centre, John Street, Sheffield S2 4SU, UK.
Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK.
Eur J Pharm Sci. 2014 Jun 16;57(100):280-91. doi: 10.1016/j.ejps.2013.08.018. Epub 2013 Aug 26.
Oral bioavailability is a key consideration in development of drug products, and the use of preclinical species in predicting bioavailability in human has long been debated. In order to clarify whether any correlation between human and animal bioavailability exist, an extensive analysis of the published literature data was conducted. Due to the complex nature of bioavailability calculations inclusion criteria were applied to ensure integrity of the data. A database of 184 compounds was assembled. Linear regression for the reported compounds indicated no strong or predictive correlations to human data for all species, individually and combined. The lack of correlation in this extended dataset highlights that animal bioavailability is not quantitatively predictive of bioavailability in human. Although qualitative (high/low bioavailability) indications might be possible, models taking into account species-specific factors that may affect bioavailability are recommended for developing quantitative prediction.
口服生物利用度是药物产品开发中的一个关键考量因素,而在临床前物种中预测人体生物利用度的做法长期以来一直存在争议。为了阐明人体与动物生物利用度之间是否存在任何相关性,我们对已发表的文献数据进行了广泛分析。由于生物利用度计算的复杂性,我们应用了纳入标准以确保数据的完整性。我们组建了一个包含184种化合物的数据库。对所报告化合物的线性回归分析表明,对于所有物种,单独或综合来看,与人体数据均无强相关性或预测性相关性。这个扩展数据集中缺乏相关性凸显出动物生物利用度无法定量预测人体生物利用度。尽管可能存在定性(高/低生物利用度)指示,但建议在进行定量预测时采用考虑到可能影响生物利用度的物种特异性因素的模型。